EGFR plays an important role in the evolution and progression of NSCLC, and some targeted therapeutic agents against EGFR have reached maturity, among which the efficacy of tyrosine kinase inhibitors (TKIs), especially for Asian populations, has been proven (65). This evidence concerns the gene EGFR and non-small cell lung carcinoma.